MedTrace Logo

Cognitive Biases Under Ketamine

NCT02235012 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2024-07-10

No results posted yet for this study

Summary

Characterise cognitive biases resulting from low dose ketamine infusion, used as a pharmacological model of psychosis.

Our assumption is that low dose ketamine results in reasoning biases by impairing the way uncertainty is monitored and taken into account for decision making.

Conditions

  • Healthy Subjects

Interventions

DRUG

Ketamine

KETAMINE PANPHARMA 250 mg/5mL, solution for infusion : * Initial rapid infusion of 0,23 mg/kg * Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min * Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

DRUG

Placebo

CHLORURE DE SODIUM 0,9 % MACOPHARMA : * Initial rapid infusion of 0,23 mg/kg * Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min * Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min

Sponsors & Collaborators

  • Fondation pour la Recherche Médicale

    collaborator OTHER

  • Fondation Fyssen

    collaborator UNKNOWN

  • Comité pour la Recherche Hospitalière Médicale

    collaborator UNKNOWN

  • Association Schizo Oui

    collaborator UNKNOWN

  • Centre Hospitalier St Anne

    lead OTHER

Principal Investigators

  • Raphaël GAILLARD · Centre Hospitalier St Anne

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
39 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-08
Primary Completion
2022-04-28
Completion
2022-04-29

Countries

  • France

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02235012 on ClinicalTrials.gov